Phase II study of vatalanib and octreotide in patients with progressive low-grade neuroendocrine tumors

Next Previous
Trial Profile

Phase II study of vatalanib and octreotide in patients with progressive low-grade neuroendocrine tumors

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Octreotide (Primary) ; Vatalanib (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 Oct 2006 Status change
    • 15 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top